Portal de Periódicos da CAPES

Treatment pathways of Japanese prostate cancer patients - A retrospective transition analysis with administrative data

2018; Public Library of Science; Volume: 13; Issue: 4 Linguagem: Inglês

10.1371/journal.pone.0195789

1932-6203

Stephane Cheung, Yukinobu Hamuro, Jörg Mahlich, Masahiko Nakayama, Akiko Tsubota,

Lung Cancer Treatments and Mutations

Limited availability of real-world data that describe treatment patterns of Japanese prostate cancer (PCA) patients.A biweekly transition analysis of PCA treatment was performed for patients with PCA diagnosis and a specific treatment between 2010 and 2015. To account for different cancer stages, two patient populations were analyzed. The first group consisted of patients on medication for hormone-sensitive prostate cancer (HSPC). The second group is comprised of patients who ended up receiving specific therapy for castration-resistant prostate cancer (CRPC). For each treatment, the average of treatment duration and the portion of patients transitioning to a consecutive treatment was calculated.We identified 59,626 patients from the Japanese administrative database with a PCA diagnosis and specific treatment. In the first year of our observational study 786 patients commenced a HSPC treatment and 695 received a CRPC specific therapy Among the HSPC group, we found that combination hormonal therapy, comprised of a gonadotrophin releasing hormone agonist or antagonist with an antiandrogen was more common than monotherapy. The results of the CRPC group indicated that chemotherapy administration was for a shorter time period in a real-world setting as compared to published clinical studies.Utilizing a novel method to visualize real-world treatment pathways for PCA patients we found that real treatment pathways are in line with international guidelines.